AU2001257168A1 - Cancer treatment - Google Patents

Cancer treatment

Info

Publication number
AU2001257168A1
AU2001257168A1 AU2001257168A AU5716801A AU2001257168A1 AU 2001257168 A1 AU2001257168 A1 AU 2001257168A1 AU 2001257168 A AU2001257168 A AU 2001257168A AU 5716801 A AU5716801 A AU 5716801A AU 2001257168 A1 AU2001257168 A1 AU 2001257168A1
Authority
AU
Australia
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001257168A
Inventor
James Berger Camden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of AU2001257168A1 publication Critical patent/AU2001257168A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001257168A 2000-04-25 2001-04-23 Cancer treatment Abandoned AU2001257168A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55845000A 2000-04-25 2000-04-25
US09558450 2000-04-25
PCT/US2001/013060 WO2001081315A2 (en) 2000-04-25 2001-04-23 Amino-imidazole derivatives for treating cancer

Publications (1)

Publication Number Publication Date
AU2001257168A1 true AU2001257168A1 (en) 2001-11-07

Family

ID=24229586

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001257168A Abandoned AU2001257168A1 (en) 2000-04-25 2001-04-23 Cancer treatment

Country Status (3)

Country Link
US (1) US20010044457A1 (en)
AU (1) AU2001257168A1 (en)
WO (1) WO2001081315A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094647A2 (en) * 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
WO2008094319A2 (en) * 2007-02-01 2008-08-07 The Board Of Regents Of The University Of Texas Sytem Methods and compositions of trail-death receptor agonists/activators

Also Published As

Publication number Publication date
US20010044457A1 (en) 2001-11-22
WO2001081315A3 (en) 2002-03-28
WO2001081315A2 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
IL251270A0 (en) Cancer treatment
AU2002223827A1 (en) Well treatment
AU2001282717A1 (en) Cancer treatment by combination therapy
AU2020501A (en) Chemotherapy treatment
AU2001252599A1 (en) Remedies for cancer
AU2001280598A1 (en) Anti-occlusion catheter
AUPQ923100A0 (en) Treatment of prostate cancer
AU2001277711A1 (en) Remedies for cisplatin-tolerant cancer
AU2002308642A1 (en) Methods for treating cancer
AU5547000A (en) Novel treatment
AU2002227925A1 (en) Human beta-defensin-3
AU2001236929A1 (en) Surface treatment
AU4556800A (en) Novel treatment
AU2002335667A1 (en) Modified reoviral therapy
AU2001257325A1 (en) Cancer treatment
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
GB0026015D0 (en) Cancer treatment
AU2001261324A1 (en) Psoriasis treatment
AU5552400A (en) Treatment of cancer
AUPQ367699A0 (en) Treatment of cancer
AU2002331816A1 (en) A cancer treatment system
AU2001289127A1 (en) Tumor treatment
AU2001257168A1 (en) Cancer treatment
AU2002351382A1 (en) Combination cancer therapy
AU2001292897A1 (en) Novel therapy